|
Total Study Population (N = 94) |
Age at procedure (years) |
|
Mean (standard deviation) |
62.1 (9.8) |
Median (Min, Max) |
64.5 (29.0, 79.0) |
Gender |
|
Female |
20 (21.3% |
Male |
74 (78.7%) |
Race |
|
African American |
8 (13.3%) |
American Indian/Alaskan Native |
1 (1.1%) |
Asian Indian |
1 (1.1%) |
Non-Hispanic or Latino |
31 (33.0%) |
White |
57 (60.6%) |
Did not identify |
2 (2.1%) |
BMI (kg/m2) |
|
Mean (standard deviation) |
30.8 (6.1) |
Median (Min, Max) |
29.9 (20.3, 49.7) |
CHA2DS2 VASc Score |
|
Mean (standard deviation) |
2.0 (1.3) |
Median (Min, Max) |
2.0 (0.0, 7.0) |
Diabetes Mellitus |
|
No |
83 (88.3%) |
Yes |
11 (11.7%) |
Hypertension |
|
No |
34 (36.2%) |
Yes |
60 (63.8%) |
Heart Failure |
|
No |
69 (73.4%) |
Yes |
25 (26.6%) |
Left Ventricular Ejection Fraction (%) |
|
Mean (standard deviation) |
55.7% (10.6) |
Median (Min, Max) |
59.0% (15.0, 69.0) |
Diastolic Dysfunction |
|
No |
47 (50.0%) |
Yes |
47 (50.0%) |
Left Atrial Volume Index |
|
Mean (standard deviation) |
41.5 (13.0) |
Median (Min, Max) |
40.5 (16.0, 78.0) |
Valvular Heart Disease |
|
No |
85 (91.4%) |
Yes |
8 (8.6%) |
Stroke or TIA |
|
No |
85 (90.4%) |
Yes |
9 (9.6%) |
Coronary Artery Disease |
|
No |
76 (80.9%) |
Yes |
18 (19.1%) |
Obstructive Sleep Apnea |
|
No |
48 (51.1%) |
Yes |
46 (43.6%) |
CPAP Therapy |
|
No |
53 (56.4%) |
Yes |
41 (43.6%) |
Autoimmune Disease |
|
No |
90 (95.7%) |
Yes |
4 (4.3%) |
Malignancy |
|
No |
90 (95.7%) |
Yes |
4 (4.3%) |
Renal Function – Creatinine |
|
Mean (standard deviation) |
1.1 (0.2) |
Median (Min, Max) |
1.1 (0.6, 1.8) |
Hepatic Function – AST, ALT |
|
Mean (SD) |
34.2 (24.0), 33.9 (35.0) |
Median (Min, Max) |
27.0 (12.0, 140.0), 29.5 (8.0, 319.0) |
Anti-inflammatory Medication |
|
No |
42 (44.7%) |
Yes |
52 (55.3%) |
Intraoperative Dexamethasone |
|
No |
60 (63.8%) |
Yes |
34 (36.2%) |
Antiarrhythmic Agent within 3 months |
|
No |
36 (38.3%) |
Yes |
58 (61.7%) |
Antiarrhythmic Agent |
|
Sotalol |
15 (25.9%) |
Dofetilide |
8 (13.8%) |
Amiodarone |
21 (36.2%) |
Flecainide |
11 (19.0%) |
Propafenone |
2 (3.4%) |
Dronedarone |
1 (1.7%) |
Antiarrhythmic Agent within 3 months to 1 year |
|
No |
57 (61.3%) |
Yes |
36 (38.7%) |
Antiarrhythmic Agent |
|
Sotalol |
11 (32.4%) |
Dofetilide |
3 (8.8%) |
Amiodarone |
10 (29.4%) |
Flecainide |
9 (26.5%) |
Propafenone |
1 (2.9%) |